Veeva RTSM vs YPrime IRT(RTSM / IRT)

Sponsors and CROs choosing a randomization and trial supply management (RTSM, also called IRT) system for interventional trials.

Scope Sponsors and CROs choosing an RTSM/IRT system to randomize participants and manage investigational product supply in interventional trials. Site-side pharmacy tools and stand-alone supply planning software are out of scope.

Guide updated How we compare

Compare within RTSM / IRT

Study fit, side by side

These notes describe the products in the RTSM / IRT guide.

Veeva RTSM

Best for
Sponsors standardizing on the Veeva Clinical Platform who want RTSM connected to Veeva EDC, eCOA and CTMS
What to consider
Veeva RTSM lists a broad set of randomization schemas and productized connections to Veeva EDC, eCOA and CTMS, and a top-20 biopharma chose it as its enterprise standard in fiscal 2026. Public material does not describe direct-to-patient shipping or a dedicated forecasting tool, and no build timeline is published.
Read product profile

YPrime IRT

Best for
Sponsors with complex randomization schemes, including minimization, who may also use YPrime eCOA
What to consider
YPrime names more randomization methods than any other vendor here, from permuted blocks to Pocock-Simon minimization, and publishes short build times. Its public IRT page does not describe supply forecasting or direct-to-patient shipping, and we found no named security certification.
Read product profile

Compare the features

Both products use the same category definitions. Product order is editorial; products are not ranked.

Full RTSM / IRT feature comparison

Single and double checks describe documented support for an individual feature. Double checks use the extended definition for that feature. Unknown means the available evidence does not establish support.

Expand a feature definition or support note for context and its original source.

Veeva RTSM vs YPrime IRT (RTSM / IRT): category feature evidence and sources. Products are not ranked.
Category featureVeeva RTSMYPrime IRT
Randomization and blinding
Feature definitions
Supported
Randomization or blinding workflows are stated.
Extended support
Named allocation methods include minimization or dynamic allocation.
Extended support

Veeva lists static, stratified, dynamic/minimization, forced and adaptive schemas, re-randomization, capping and sentinel dosing.

Source
About this support label

Named methods explicitly include dynamic allocation and minimization.

Extended support

YPrime names permuted block and stratified randomization, dynamic allocation and minimization (Pocock and Simon), stratum caps and conditional re-randomization.

Source
About this support label

Named methods include permuted blocks, dynamic allocation and minimization.

Trial supply management
Feature definitions
Supported
Drug inventory, dispensing, shipping or resupply workflows are documented.
Extended support
Supply forecasting and direct-to-patient delivery (shipping or dispensing) are both documented.
Supported

Veeva documents threshold, predictive and just-in-time resupply with expiry buffers and accountability, but no direct-to-patient shipping or separate forecasting tool.

Source
About this support label

Predictive resupply establishes base support; direct-to-patient shipping is not documented.

Supported

The IRT page covers inventory, orders, resupply, kit replacement and depot rules, but does not describe supply forecasting or direct-to-patient shipping.

Source
About this support label

Inventory and resupply establish base support; forecasting and direct-to-patient shipping are not described.

Study build speed and mid-study changes
Feature definitions
Supported
Study setup or post-go-live study changes are described.
Extended support
Study setup is described, and post-go-live changes explicitly avoid interrupting live study use.
Supported

Authorized users can switch on cohorts and change limits mid-study, and Veeva says design-change amendments often take days rather than weeks; no initial build timeline is published.

Source
About this support label

Mid-study cohort and limit changes are stated; an initial build timeline and uninterrupted changes are not established.

Supported

YPrime cites build to go-live in under four weeks for an early-phase oncology trial, about a week for the simplest designs, and self-service routine changes that take effect immediately.

Source
About this support label

Build timelines and immediately effective routine changes are stated; uninterrupted live use is not explicit.

Integrations and platform
Feature definitions
Supported
Integration or data exchange with another system or application is described.
Extended support
Integration with a clinical-trial application plus an API for integration are both stated.
Supported

Productized connections send data to Veeva EDC, eCOA and DQS and take site data from Veeva CTMS, and the brief cites third-party EDC and shipping-provider connections.

Source
About this support label

Native and external trial-system connections establish base support; an API is not stated in this note.

Supported

YPrime documents integrations with EDC, eCOA, eConsent, CTMS, labs, distribution systems and data lakes, and runs its own eCOA.

Source
About this support label

Trial-system integrations establish base support; an API is not stated in this note.

Compliance and security evidence
Feature definitions
Supported
Relevant trial compliance or security controls are stated, with their scope identified.
Extended support
Relevant trial controls and a publicly accessible ISO certificate or SOC audit report covering the product or vendor are documented.
Supported

Veeva's trust page lists ISO 27001 audits and a SOC 2 Type II report, but we found no RTSM-specific Part 11 or Annex 11 statement.

Source
About this support label

Vendor security audits are listed; RTSM-specific trial controls and public document access are not established.

Supported

YPrime's trust page lists 21 CFR Part 11, GDPR and HIPAA compliance, but we found no ISO 27001 or SOC 2 attestation.

Source
About this support label

Trial and privacy standards are stated; ISO/SOC attestation evidence was not found.

Track record
Feature definitions
Supported
Published product or wider-platform adoption, or a named clinical-research deployment.
Extended support
Product-specific study, customer, institution, site or participant figures plus a published country count establish international use.
Supported

Veeva reports that a top-20 biopharma selected Veeva RTSM as its enterprise standard (fiscal 2026); no total study or customer count for RTSM is published.

Source
About this support label

An enterprise-standard selection provides base track-record evidence; product-specific adoption figures are not published.

Supported

YPrime reports 55,000+ sites and 300,000+ patients supported and 20+ years of IRT work, but publishes no study count.

Source

The guide update date reflects guide edits. Vendor statements are attributed in the evidence.

Keep the category in view

Compare these products with the other tools in the RTSM / IRT guide using the same feature definitions.

More RTSM / IRT comparisons featuring one of these products.